• Calendar
  • Contact
  • Equity Programs
  • Public Resources
  • Where to Buy
Cannabis Control Commission Massachusetts
  • Home
  • Patients and Caregivers
  • Applicants and Licensees
  • Adult Consumers
  • Parents
  • State and Local Government
  • Certifying Healthcare Providers
  • Search
  • Menu Menu

News / Media Hits / Boston Globe | Can Massachusetts lead the way in medical cannabis research? (Op-Ed)

January 12, 2026

Boston Globe | Can Massachusetts lead the way in medical cannabis research? (Op-Ed)

By Shannon O’Brien, Chair, Cannabis Control Commission and Julie K. Johnson, Chief of Research, Cannabis Control Commission

Whether cannabis is used for recreation or to treat conditions ranging from chronic pain to sleep disorders, President Trump’s executive order initiating the process to reschedule cannabis is a pivotal step toward maximizing the benefits of cannabis while minimizing its risks.

If fully implemented, rescheduling — paired with an effort to advance rigorous research — would represent a consequential shift in federal drug policy. For more than 50 years, cannabis has remained in the most restrictive federal category, alongside substances such as heroin. This status has significantly impeded high-quality clinical research and limited the development of evidence-based guidance for patients and clinicians. Rescheduling would help open the door to large-scale, collaborative scientific studies examining cannabis and hemp-derived cannabinoids for medicinal use.​

Research shows that tens of millions of Americans use cannabis: Among adults age 19 to 30, about 42 percent reported cannabis use during the past year, and levels reached 29 percent among those age 35 to 50, according to a 2023 survey funded by the National Institutes of Health. Yet science that should guide how cannabis is used lags behind real-world practice, leaving patients and health care providers to make decisions without the level of evidence that is standard for other treatments. This gap is particularly troubling in areas such as chronic pain management, mental health, and sleep, as patients may substitute cannabis for more established therapies without medical guidance.​

Despite its unmatched concentration of academic medical centers and research universities, Massachusetts is no longer at the forefront of medical cannabis research. States such as Pennsylvania have established formal partnerships among regulators, universities, and licensees to study conditions including cancer, epilepsy, chronic pain, and opioid reduction, embedding research protocols directly into their medical cannabis programs. As a result of the lack of research in Massachusetts, patients here often rely on products and regimens that have not been evaluated with the rigor expected in the health care system.​

The Massachusetts Cannabis Control Commission plays a leading role as a widely respected voice on cannabis research and regulatory policy. Building on that role, commission leaders are working with stakeholders including other cannabis regulators, academic and industry researchers, and the University of Massachusetts to define a vision for a multidisciplinary Center for Cannabis Research and Policy that would unite social policy research with biomedical and clinical studies to assess how cannabis affects human health across populations.

The Legislature showed foresight in 2017 in directing the commission to produce an annual research report on the health and social impacts of cannabis, providing policy makers with evidence to better protect Massachusetts citizens. Commissioners are pursuing a review to streamline regulations that disincentivize serious research investment into the effects of cannabis.​

The proposed Center for Cannabis Research and Policy would serve as a statewide hub connecting public agencies, academic medical centers, and licensed operators. The commission has won numerous research grants, but as an independent government agency, it currently lacks a financial mechanism under state law allowing it to accept these funds.

###

Continue reading the full Op-Ed by Cannabis Control Commission Chair, Shannon O’Brien and Chief of Research, Julie K. Johnson in the Boston Globe here: https://www.bostonglobe.com/2026/01/12/opinion/cannabis-medical-research-massachusetts-center/

Get Notified

Subscribe for updates from the Cannabis Control Commission.

Sign up for Updates
ccc logo
  • Home
  • Patients and Caregivers
  • Applicants and Licensees
  • Adult Consumers
  • Parents
  • State and Local Government
  • Certifying Healthcare Providers
  • Calendar
  • Contact
  • Equity Programs
  • Public Resources
  • Where to Buy
  • About
  • Careers
  • Enforcement Announcements
  • FAQs
  • News
  • Open Data
  • Press and Media
  • Public Health and Safety Advisories
  • Research

Affiliate Sites

  • MMJOS
  • MassCIP
  • Metrc
  • MoreAboutMJ.org
  • EquityWorks Career Hub
  • HelplineMA.org
Twitter Facebook LinkedIn YouTube
© Commonwealth of Massachusetts Cannabis Control Commission
Massachusetts Adult-use Cannabis Sales Generated $1.65 Billion Total In 202...Bulletin – Massachusetts Commission for the Blind Identification Card
Scroll to top